Oslo, Norway, 9 October 2019

Nordic Nanovector ASA (OSE: NANO) announces that the Company and its
collaborators at Orano Med will present data and analyses from preclinical
studies with [212]Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the
treatment of leukaemia and lymphoma at the 2019 Annual Congress of the European
Association of Nuclear Medicine (12-16 October, Barcelona, Spain).

In the study, the efficacy of [212]Pb-NNV003 was compared with ibrutinib in a
disseminated mouse model using the ibrutinib-resistant cell line MEC-2.
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that forms part of the
standard of care for chronic lymphocytic leukaemia (CLL) and non-Hodkgin's
lymphoma (NHL), alongside chemotherapy and anti-CD20 antibody therapy.

The study showed that a single injection of [212]Pb-NNV003 is safe and effective
for the treatment of CD37-positive CLL and NHL in preclinical models, with
promising efficacy in an ibrutinib-resistant CLL model.

Presentation details are as follows:

Targeted alpha therapy with [212]Pb-NNV003 is efficient in treatment of
ibrutinib-resistant chronic lymphocytic leukaemia in preclinical model

Authors:             A. Saidi, H. Heyerdahl, A.F. Maaland, J. Torgue, and J.
Dahle

Session:             405 - M2M - Parallel Session: Antibody-Based Radionuclide
Therapy

Abstract:            OP-134

Date / time:        Sunday 13 October, 14:30-14:41 CEST

The abstract book can be downloaded at https://eanm19.eanm.org/abstract-book/



For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements.  These
statements are based on management's current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.